An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) has announced that RA Session II, its President and CEO, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 AM ET. The presentation will focus on Taysha's mission to develop AAV-based gene therapies aimed at treating monogenic diseases of the central nervous system. A webcast of the presentation will be accessible in the 'Events & Media' section of Taysha's website, with archived access available for 60 days.
Positive
None.
Negative
None.
DALLAS--(BUSINESS WIRE)--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:00 AM Eastern Time.
A webcast of the presentation will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcast will be available on the website for 60 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
What is Taysha Gene Therapies' presentation about at the J.P. Morgan Healthcare Conference on January 13, 2022?
Taysha Gene Therapies will present a corporate overview focused on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.
What time is Taysha Gene Therapies' presentation scheduled at the J.P. Morgan Healthcare Conference?
The presentation by Taysha Gene Therapies is scheduled for 9:00 AM ET on January 13, 2022.
How can I access the Taysha Gene Therapies presentation from the J.P. Morgan Healthcare Conference?
You can access the presentation via a webcast available in the 'Events & Media' section of Taysha Gene Therapies' corporate website.
Is there an archived version of Taysha Gene Therapies' presentation available?
Yes, an archived version of the presentation will be available on Taysha Gene Therapies' website for 60 days after the event.
What is the stock symbol for Taysha Gene Therapies?
The stock symbol for Taysha Gene Therapies is TSHA.
